Effects of Peptidoglycan and Polyinosinic: Polycytidylic Acid on the Recombinant Subunit Vaccine Efficacy Against Edwardsiella tarda in Japanese Flounder Paralichthys olivaceus
The protective effects of a subunit vaccine, a recombinant protein of Edwardsiella tarda glyceraldehyde 3-phosphate dehydrogenase (Rec) combined with peptidoglycan (PGN) and polyinosinic:polycytidylic acid (polyIC), against edwardsiellosis in Japanese flounder Paralichthys olivaceus were investigate...
Gespeichert in:
Veröffentlicht in: | Fish Pathology 2021/09/15, Vol.56(3), pp.149-155 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The protective effects of a subunit vaccine, a recombinant protein of Edwardsiella tarda glyceraldehyde 3-phosphate dehydrogenase (Rec) combined with peptidoglycan (PGN) and polyinosinic:polycytidylic acid (polyIC), against edwardsiellosis in Japanese flounder Paralichthys olivaceus were investigated to evaluate an adjuvant property of pathogen-associated molecular patterns. By injection of the mixture of the recombinant protein plus peptidoglycan and polyIC (Rec + PGN and Rec + IC, respectively), the interleukin-1β and interferon (IFN)-γ mRNA levels were upregulated in comparison to injection of phosphate-buffered saline (PBS). In addition, type I IFN mRNA was induced in the Rec + IC group. Although antibody titers were increased not only in the recombinant injected Rec group but also in the Rec + PGN and Rec + IC groups, the Rec + PGN and Rec + IC values were slightly higher and lower than those of the Rec group, respectively. After the challenge test with E. tarda, the Rec + IC group showed a higher survival rate than the PBS group, whereas the rates of the Rec and Rec + PGN groups were lower than the PBS group. Furthermore, bacteria were reisolated from only 1 out of 16 survivors in the Rec + IC group. These results suggested that polyIC might be a candidate for a vaccine adjuvant for intracellular bacterial infection. |
---|---|
ISSN: | 0388-788X 1881-7335 |
DOI: | 10.3147/jsfp.56.149 |